At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 137 enrolled
Drug / intervention
Peramivir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza
In Brief
A Phase 3 clinical trial evaluating Peramivir and Oseltamivir for Influenza. Completed, enrolled 137 participants across 10 sites in 2 countries.
Detailed Summary
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated influenza.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSouth Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionOct 2019
Study CompletionMay 2020
TodayJul 2026
First PostedFeb 23, 2015
Enrollment StartMar 11, 2015
Primary CompletionOct 28, 2019
Study CompletionMay 14, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.4 years ago
Interventions
Peramivirdrug
Oseltamivirdrug